Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousGraft vs Leukemia EffectPeripheral Blood Stem Cell TransplantationTransplantation ChimeraTissue DonorsMyeloablative AgonistsTreatment OutcomeBone Marrow TransplantationBusulfanGraft vs Tumor EffectHistocompatibilityChimerismRecurrenceWhole-Body IrradiationRetrospective StudiesLeukemiaHistocompatibility TestingStem CellsAllograftsVidarabineGraft SurvivalHematologic DiseasesCord Blood Stem Cell TransplantationMyelodysplastic SyndromesLeukemia, Myeloid, AcuteSiblingsLymphocyte TransfusionHLA AntigensImmunosuppressive AgentsRemission InductionHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival RateCytomegalovirus InfectionsSurvival AnalysisTransplantation ImmunologyAcute DiseaseTime FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemic InfiltrationCombined Modality TherapyDisease-Free SurvivalCystitisAnemia, AplasticTransplantation, IsogeneicT-LymphocytesMinor Histocompatibility AntigensHematopoiesisOpportunistic InfectionsLymphocyte DepletionHematopoietic Stem Cell MobilizationMultiple MyelomaSevere Combined ImmunodeficiencyNeoplasm, ResidualFlow CytometryFollow-Up StudiesSalvage TherapyLymphoproliferative DisordersAntigens, CD34Antilymphocyte SerumCyclophosphamideCytomegalovirusBronchiolitis ObliteransBone Marrow CellsLiver TransplantationRisk FactorsMice, Inbred C57BLImmunocompromised HostBlood Group IncompatibilityPhotopheresisMycosesCell DifferentiationPrognosisImmunosuppressionFatal OutcomeLeukemia, MyeloidAntineoplastic Combined Chemotherapy ProtocolsSurvivorsPrimary MyelofibrosisMesenchymal Stem Cell TransplantationGanciclovirFetal BloodCell TransplantationUnrelated DonorsCell LineageIsoantigensChronic DiseaseCytarabineIncidenceStem Cell NicheGraft RejectionEmbryonic Stem CellsCyclosporine